Second Circuit Court Upholds Purdue Pharma's Plan of Reorganization on Appeal
Today, the U.S. Court of Appeals for the Second Circuit ruled in favor of Purdue Pharma's chapter 11 Plan of Reorganization (the "Plan"), affirming the bankruptcy court's September 2021 confirmation order.
"The Second Circuit's ruling is a victory for Purdue's creditors, including all 50 states, local governments, and victims who overwhelmingly support the Plan of Reorganization. Our focus going forward is to emerge from bankruptcy and deliver billions of dollars of value for victim compensation, opioid crisis abatement, and overdose rescue medicines," said Steve Miller, who joined Purdue in mid-2018 as chairman of its Board of Directors. "We have nearly unanimous creditor support earned through productive negotiations and a collective focus on the public good. Our creditors understand the Plan is the best option to provide assistance to those who need it most, the most fair and expeditious way to resolve the litigation, and the only way to deliver billions of dollars in value specifically to fund opioid crisis abatement efforts."
The Plan is supported by virtually all governmental and non-governmental creditors, including states, local governments, personal injury victims, schools, hospitals, and others. Once consummated, the Plan will deliver billions of dollars of value to fund programs specifically for abatement of the opioid crisis. Upon emergence, Purdue Pharma will cease to exist and a new company, Knoa Pharma, will emerge with a uniquely public-minded mission.
Knoa Pharma Highlights
Knoa Pharma will be governed by new independent board members selected by the stakeholders. It will operate in a responsible and sustainable manner taking into account long-term public health interests relating to the opioid crisis.
Knoa Pharma will be subject to operating covenants to ensure that all of its products, including all opioid products, are provided in a safe manner that limits the risk of diversion. It will be held to the highest standards of conduct and required to comply with a detailed injunction (as Purdue is now) restricting the promotion of opioid products. An independent Monitor will continue to ensure that the new company complies with the court-ordered injunction, and will report regularly on compliance.
Knoa Pharma will develop and distribute opioid addiction treatment and overdose reversal medicines at no profit. It will also continue serving patients and consumers who rely on Purdue's existing medicines and products, and it will utilize its scientific capabilities to bring to market other potentially life-saving medicines in its pipeline.
Knoa Pharma will have a diverse portfolio and pipeline of medicines in development that address important medical needs in multiple therapeutic areas such as oncology and central nervous system disorders.
Knoa Pharma will be ultimately owned by a trust that will be established to fund opioid crisis abatement efforts in satisfaction of the claims brought by states and localities, as well as an opioid abatement trust established for the benefit of Native American Tribes (the "Tribe Trust"). Proceeds will also flow to opioid abatement trusts established for the benefit of other creditors such as hospitals, schools, and children with a history of Neonatal Abstinence Syndrome and their guardians, and to a fund for the benefit of personal injury victims.
Knoa Pharma will commence doing business once Purdue's plan of reorganization becomes effective.
The Sackler families will have no involvement in Knoa Pharma.
Purdue Pharma and its subsidiaries develop, manufacture and market medications and consumer health products to meet the evolving needs of healthcare professionals, patients, consumers and caregivers. Once consummated, Purdue's plan of reorganization will deliver billions in value to communities across the country to fund programs specifically for abatement of the opioid crisis. The Plan will also deliver funds to private abatement trusts for the benefit of personal injury claimants.
Substantially all of Purdue's assets would be transferred to a new post-emergence company with a public-minded mission. This new company would be governed by new independent board members, and would operate in a responsible and sustainable manner taking into account long-term public health interests relating to the opioid crisis. The company would continue serving patients and consumers who rely on its medicines and products, pursuing its pipeline, and introducing medicines that will help save and improve lives.
On or around February 6, 2024, Hypertension-Nephrology Associates, P.C. ("the Practice") became aware it was the target of an extortion attack when an extortion note was found on its computer system. Upon discovery of the extortion note, the Practice...
Dr. Scott McMahon of Whole World Health Care is happy to announce the 2024 annual Surviving Mold-CIRSx Conference, set to be held May 16-19, 2024 at the Hyatt Regency, located at 2615 Preston Road in Frisco, Texas, a city near Dallas. CIRSx was...
PDS Health®, a leading U.S. provider of integrated healthcare support services, proudly announces its recognition as one of The Civic 50 honorees of 2024 by Points of Light, the world's largest nonprofit dedicated to accelerating people-powered...
Note: All times local
Quebec City, Quebec
9:30 a.m.
The Prime Minister will take part in an historic announcement about the Québec Bridge. The Minister of Public Services and Procurement, Jean-Yves Duclos, and the Minister of Transport and Quebec...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for...
Andlauer Healthcare Group Inc. ("AHG" or the "Company") today announced that the Board has approved a substantial issuer bid (the "Offer") under which the Company will offer to purchase for cancellation up to 2,000,000 subordinate voting shares of...